Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 77 | 4,673 | 44% |
| 2020 | 74 | 4,065 | 46% |
| 2021 | 81 |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 30% of the cases CMS names in Arizona; 50 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 239 | 12,086−4.4%/yr | −4.4%/yr | 3.7 | 4% | 12,400 in 2030+0.5%/yr |
| Washington | 61 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| LAA occlusion & loop recorders | 106 | 4,739+15%/yr | +15%/yr | 5.62.3× | 41% | 7,950 in 2030+9%/yr |
| EP ablation |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
| 2024 |
| 4,095 |
| 54% |
| 2025 est. | ≈ 4,100 | – |
| 2026 est. | ≈ 4,170 | – |
| 4,048 |
| 49% |
| 2022 | 80 | 4,025 | 51% |
| 2023 | 81 | 4,098 | 53% |
| 2024 | 85 | 4,095 | 54% |
| 2025 from claims | – | 4,104 3,766–4,342 | 55% |
| 2026 forecast | – | 4,174 3,672–4,816 | 55% |
| 2027 forecast | – | 4,226 3,613–5,037 | 56% |
| 2028 forecast | – | 4,280 3,571–5,240 | 56% |
| 2029 forecast | – | 4,333 3,539–5,434 | 57% |
| 2030 forecast | – | 4,387 3,515–5,622 | 57% |
In 2025, 40% inpatient hospital, 34% hospital outpatient, 26% surgery center. The share outside the hospital has moved +11 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~4,200 | ~1,700 | ~1,400 | ~1,100 |
| 2027 · ~4,200 | ~1,700 | ~1,400 | ~1,100 |
| 2028 · ~4,300 | ~1,700 | ~1,400 | ~1,100 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 33% (34% in 2025).
| 2,895−4.3%/yr |
| −4.3%/yr |
| 3.9 |
| 0% |
| 2,950 in 2030+0.3%/yr |
| Colorado | 38 | 1,903−1.6%/yr | −1.6%/yr | 4.1 | 0% | 2,210 in 2030+2.5%/yr |
| Oregon | 32 | 1,588−2.2%/yr | −2.2%/yr | 4.0 | 3% | 1,810 in 2030+2.2%/yr |
| Nevada | 21 | 1,111−3%/yr | −3%/yr | 4.0 | 2% | 1,240 in 2030+1.8%/yr |
| Utah | 22 | 921−2.8%/yr | −2.8%/yr | 4.4 | 0% | 900 in 2030−0.4%/yr |
| Montana | 15 | 883+1.5%/yr | +1.5%/yr | 4.7 | 0% | 880 in 20300%/yr |
| Idaho | 16 | 883+3.2%/yr | +3.2%/yr | 4.5 | 0% | 1,260 in 2030+6.1%/yr |
| New Mexico | 11 | 618−2.3%/yr | −2.3%/yr | 2.8 | 0% | 670 in 2030+1.3%/yr |
| Alaska | 6 | 384−0.5%/yr | −0.5%/yr | 3.2 | 26% | 440 in 2030+2.2%/yr |
| Wyoming | 3 | 122+2.7%/yr | +2.7%/yr | 1.1 | 0% | 190 in 2030+7.7%/yr |
| Hawaii | 3 | 114−16%/yr | −16%/yr | 0.9 | 0% | 130 in 2030+2.8%/yr |
| 62 |
| 3,909+7.7%/yr |
| +7.7%/yr |
| 4.41.6× |
| 0% |
| 6,260 in 2030+8.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 37% of company spending on these surgeons in 2025, +16 pts on 2024.
In 2025, 8 companies reported engagement with Arizona’s surgeons worth $350K in consulting, speaking, meals and travel tied to these products, about $4,123 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.